Search results for " vaccine"

showing 10 items of 680 documents

2013

Annual influenza vaccination is recommended for healthcare workers, but many do not follow the recommendation. The objective of this study was to investigate the factors associated with seasonal influenza vaccination in the 2011–2012 season. We carried out an anonymous web survey of Spanish primary healthcare workers in 2012. Information on vaccination, and knowledge and attitudes about the influenza vaccine was collected. Workers with medical conditions that contraindicated vaccination and those with high risk conditions were excluded. Multivariate analysis was performed using unconditional logistic regression. We included 1,749 workers. The overall vaccination coverage was 50.7% and was h…

MultidisciplinaryMultivariate analysisbusiness.industryInfluenza vaccineViral VaccinePrimary health careLogistic regressionSeasonal influenzaVaccinationEnvironmental healthHealth careImmunologyMedicinebusinessPLOS ONE
researchProduct

Withdrawal of a mumps vaccine.

1994

Mumps vaccinebusiness.industryImmunization ProgramsPediatrics Perinatology and Child HealthMedicineHumansMumps VaccinebusinessVirologyMeningitis ViralUnited KingdomEuropean journal of pediatrics
researchProduct

Study of ovine immune response against Mycoplasma agalactiae during natural and experimental infection and comparison of different vaccine formulatio…

2012

Mycoplasma agalactiaeSettore MED/04 - Patologia Generaleovinevaccineinfectionovine; Mycoplasma agalactiae; infection; vaccine;
researchProduct

Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

2018

PURPOSE: To evaluate the oncological impact of postponing radical cystectomy (RC) to allow further conservative therapies prior to progression in a large multicentre retrospective cohort of T1-HG/G3 patients initially treated with BCG. METHODS: According to the time of RC, the population was divided into 3 groups: patients who did not progress to muscle-invasive disease, patients who progressed before radical cystectomy and patients who experienced progression at the time of radical cystectomy. Clinical and pathological outcomes were compared across the three groups. RESULTS: Of 2451 patients, 509 (20.8%) underwent RC. Patients with tumors > 3 cm or with CIS had earlier cystectomies (HR = 1…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyKaplan-Meier EstimateSettore MED/24 - UrologiaCohort Studies0302 clinical medicineRetrospective StudieMultivariate AnalysiOutcomeeducation.field_of_studyHigh riskBladder cancerMiddle AgedPrognosisEditorialTreatment OutcomeLocal030220 oncology & carcinogenesisBCG VaccineFemaleSurvival AnalysiBladder cancer; Cystectomy; Extravesical disease; High risk; Outcomes; T1G3; UrologyHumanmedicine.medical_specialtyPrognosiUrologyPopulationUrologyOutcomesT1G3CystectomyRisk AssessmentDisease-Free SurvivalCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansNeoplasm InvasivenesseducationSurvival analysisProportional Hazards ModelsRetrospective StudiesAgedNeoplasm StagingNeoplasm InvasiveneCarcinoma Transitional CellBladder cancerbusiness.industryProportional hazards modelBladder cancer; Cystectomy; Extravesical disease; High risk; Outcomes; T1G3; Aged; BCG Vaccine; Carcinoma Transitional Cell; Cohort Studies; Cystectomy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder NeoplasmsCarcinomaRetrospective cohort studymedicine.diseaseSurvival AnalysisNeoplasm RecurrenceUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisProportional Hazards ModelTransitional CellCohort StudieNeoplasm Recurrence LocalbusinessExtravesical disease
researchProduct

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as pr…

2018

PURPOSE: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. METHODS: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (7…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyNon-muscle invasive bladder cancer · Re-transurethral resection of the bladder · Recurrence · ProgressionSettore MED/24 - Urologia0302 clinical medicineRetrospective StudieRe-transurethral resection of the bladderRecurrenceImmunologicCause of DeathCumulative incidenceStage (cooking)Cause of deathProgressionIntravesicalAdministration IntravesicalLocal030220 oncology & carcinogenesisAdministrationBCG VaccineDisease ProgressionFemaleNon-muscle invasive bladder cancerHumanReoperationmedicine.medical_specialtyUrologyUrologyCystectomyArticleFollow-Up StudieCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansAdjuvantsAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesBladder cancerProportional hazards modelbusiness.industryNon-muscle invasive bladder cancer; Progression; Re-transurethral resection of the bladder; Recurrence; Adjuvants Immunologic; Administration Intravesical; Aged; BCG Vaccine; Cause of Death; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence Local; Neoplasm Staging; Proportional Hazards Models; Reoperation; Retrospective Studies; Urinary Bladder NeoplasmsRetrospective cohort studymedicine.diseaseNeoplasm RecurrenceUrinary Bladder NeoplasmsProportional Hazards ModelNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007.

2013

Contribution over time of human papillomavirus (HPV) types in human cancers has been poorly documented. Such data is fundamental to measure current HPV vaccines impact in the years to come. We estimated the HPV type-specific distribution in a large international series of invasive cervical cancer (ICC) over 70 years prior to vaccination. Paraffin embedded ICC cases diagnosed between 1940 and 2007 were retrieved from eleven countries in Central-South America, Asia and Europe. Included countries reported to have low-medium cervical cancer screening uptake. Information on age at and year of diagnosis was collected from medical records. After histological confirmation, HPV DNA detection was per…

OncologyAdultCancer ResearchInvasive cervical cancermedicine.medical_specialtyAsiavirusesUterine Cervical NeoplasmsHPV vaccinesLogistic regressionInternal medicinemedicineHumansNeoplasm InvasivenessHuman papillomavirusEarly Detection of CancerAgedRetrospective StudiesGynecologyCervical cancerHuman papillomavirus 16Paraffin EmbeddingHuman papillomavirus 18business.industryTime trendsMedical recordvirus diseasesCentral AmericaMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsVaccinationEuropeLogistic ModelsOncologyDNA ViralFemalebusinessInternational journal of cancer
researchProduct

Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention

2011

Objective. Human papillomavirus (HPV) genotype distribution in invasive cervical cancer (ICC) is critical to guide the introduction and to assess the impact of HPV prophylactic vaccines. This study aims to provide specific information for Spain. Methods. 1043 histological confirmed ICC cases diagnosed from 1940 to 2007 from six Spanish regions were assembled. HPV DNA detection was performed by SPF10 broad-spectrum PCR followed by deoxyribonucleic acid enzyme immunoassay and genotyping by reverse hybridization line probe assay (LiPA(25)) (version 1). Results. Of 1043 ICC cases, 904 were HPV DNA positive (adjusted prevalence: 89.1%). The eight most common types, in decreasing order, were HPV …

OncologyAdultmedicine.medical_specialtyInvasive cervical cancerGenotypeUterine Cervical NeoplasmsHPV vaccinesAdenocarcinomaAlphapapillomavirusInternal medicineGenotypemedicineHumansPapillomavirus VaccinesHuman papillomavirusGenotypingAgedGynecologyCervical cancerHuman papillomavirus 16HPV typesVaccinesHpv typesHuman papillomavirus 18business.industryHPV PositivePapillomavirus Infectionsvirus diseasesObstetrics and GynecologyTime trendsMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsOncologySpainCervical cancerFemalebusiness
researchProduct

Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in S…

2017

ABSTRACT While bivalent and quadrivalent HPV vaccines have been used for about 10 years, a nonavalent vaccine against HPV types 6/11/16/18/31/33/45/52 and 58 has been recently approved by FDA and EMA and is now commercially available. The objective of our study was to evaluate the potential impact of the nonavalent vaccine on HPV infection and related low- and high-grade squamous intraepithelial lesions (LSIL, HSIL), compared to the impact of the quadrivalent vaccine, in a female population living in Sicily (Italy). Low estimates of HPV vaccine impact were calculated as prevalence of HPV 6/11/16/18/31/33/45/52 and 58 genotypes, alone or in association, but excluding presence of other HPV ty…

OncologyAdultmedicine.medical_specialtyReferralGenotypeImmunologyUterine Cervical NeoplasmsHPV vaccinesCervix UteriHospital based study03 medical and health sciences0302 clinical medicineHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Internal medicinevaccineGenotypemedicinePrevalenceHumansImmunology and Allergy030212 general & internal medicinePapillomavirus VaccinesquadrivalentReferral and ConsultationSicilyFemale populationsquamous intraepithelial lesionGynecologyPharmacologyPotential impactHpv typesbusiness.industryPapillomavirus InfectionsHPV infectionsquamous intraepithelial lesionsvirus diseasesmedicine.diseaseUterine Cervical DysplasiaResearch Papersimpact estimateHPV infection; impact estimate; nonavalent; quadrivalent; squamous intraepithelial lesions; vaccine; Immunology and Allergy; Immunology; Pharmacology030220 oncology & carcinogenesisHPV infectionFemalebusinessnonavalent
researchProduct

Abstract B072: Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy in patients with stage IV non-small cell lung…

2016

Abstract Background: Preclinical studies demonstrated that local radiotherapy (RT) acts synergistically with RNActive mRNA vaccines to enhance anti-tumor effects and increase tumor-infiltrating lymphocytes. BI 1361849 is a therapeutic vaccine comprising optimized mRNA constituents encoding six NSCLC-associated antigens. Interim data of a phase Ib study, employing local RT to increase the immune mediated tumor control by BI 1361849, have been previously published (J Clin Oncol 34, 2016, suppl; abstr e20627). Here we report results of immune response analyses as well as updated safety and efficacy data. Methods: Patients (pts) with stage IV NSCLC were enrolled in three cohorts based on histol…

OncologyCancer Researchmedicine.medical_specialtyChemotherapybiologybusiness.industrymedicine.medical_treatmentImmunogenicityImmunologyCancermedicine.diseasePemetrexedImmune systemCancer immunotherapyInternal medicineImmunologymedicinebiology.proteinCancer vaccineEpidermal growth factor receptorbusinessmedicine.drugCancer Immunology Research
researchProduct

Abstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

2016

Abstract One of the hallmarks of cancer is the inherent instability of the genome leading to multiple genomic alterations and epigenetic changes that ultimately drive carcinogenesis. These processes lead to a unique molecular profile of every given tumor and to substantial intratumoral heterogeneity of cancer tissues. Recently, a series of independent reports revealed that pre-formed neoantigen specific T-cell responses are of crucial relevance for the clinical efficacy of immune checkpoint inhibitors. However, spontaneous immune recognition of neoantigens seems to be a rare event with only less than 1% of mutations inducing a T-cell response in the tumor-bearing patient. Accordingly, only …

OncologyCancer Researchmedicine.medical_specialtyMutationbusiness.industryImmunogenicityMelanomaCancermedicine.diseasemedicine.disease_causeClinical trialThe Hallmarks of CancerOncologyInternal medicineImmunologymedicineCancer vaccinebusinessCarcinogenesisCancer Research
researchProduct